By month 4 and beyond, most participants report feeling essentially normal with no regular nausea
The term describes facial hollowing, looser skin, deeper folds, and a more aged appearance that can become noticeable after substantial weight loss on semaglutide, tirzepatide, or another GLP-1 medication
However, nausea is the most commonly reported adverse effect, with incidence varying by medication and dose: approximately 15-30% for most GLP-1 agonists and up to 30-44% at higher doses of semaglutide and tirzepatide according to FDA prescribing information
How much weight can you expect to lose with Ozempic as a GLP-1 medication
Other analysts have cautioned against putting too much stock in the rate of dropouts, arguing that clinical trial designs do not fully reflect how the drug may be used in practice, including more flexible dosing and patient selection
Results vary by individual